Across TCGA pan-cancer cohorts, PCLO mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PCLO data layer compared with 25 for mass-spec protein and 14 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PCLO mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PCLO expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

UCEC, GBM, and PDAC are the cancer types where PCLO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Quartile	III,IV	1.000	0.296	.040	12	view →
GBM	DFS	Quartile	All	0.908	0.695	.017	3	view →
PDAC	DFS	Median	II,III,IV	0.666	0.761	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PCLO tumor-vs-normal RNA expression · all PCLO data types